Clinical value of PTEN in patients with superficial bladder cancer

Urologia Internationalis

Volumn 80, Issue 3, 2008, Pages 264-269

  Han, Kyung Seok ^a   Jeong, In Gab ^a   Joung, Jae Young ^a   Yang, Seung Ok ^a   Chung, Jinsoo ^a   Seo, Ho Kyung ^a   Kwon, Kyung Suk ^a   Park, Weon Seo ^a   Lee, Kang Hyun ^a  

^a National Cancer Center   (South Korea)

Author keywords

Bladder cancer, prognosis; Immunohistochemistry; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CARCINOMA IN SITU; CELL GRANULE; CONTROLLED STUDY; CYSTECTOMY; DISEASE COURSE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION;

DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PTEN PHOSPHOHYDROLASE; URINARY BLADDER NEOPLASMS;

EID: 43749106684     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127338     Document Type: Article

References (16)

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
2. Oxford G, Theodorescu D: The role of Ras superfamily proteins in bladder cancer progression. J Urol 2003;170:1987-1993.
3. Malkowicz SB: Management of superficial bladder cancer;in Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds): Campbell's Urology, ed 8. Philadelphia, Saunders, 2002, vol 4, chapt 77, pp 2785-2802.
4. Johannes AW: Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006;49:790-797.
5. Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, et al: Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003;43:351-361.
6. Wu X, Obata T, Khan Q, Highshaw RA, White DV, Sweeney C: The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004;93:143-150.
7. Latini JM, Rieger-Christ KM, Wang DS, Silverman ML, Libertino JA, Summerhayes IC: Loss of heterozygosity and microsatellite instability at chromosomal sites 1q and 10q in morphologically distinct regions of late stage prostate lesions. J Urol 2001;166:1931-1936.
8. Koskal IT, Yasar D, Dirice E, Usta MF, Karauzum S, Luleci G, et al: Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol Int 2005;75:102-106.
9. Nieder AM, Brausi M, Lamm D, O'Donnel M, Tomita K, Woo H, et al: Management of stage T1 tumors of the bladder: international consensus panel. Urology 2005;66:108-125.
10. Saint F, Le Frere Belda MA, Quintela R, et al: Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette-Guérin (BCG). Eur Urol 2004;45:475-482.
11. Esrig D, Elmajian D, Groshen A, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264.
12. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al: PTEN, a putative protein tyrosine phosphate gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1876-1878.
13. Steck PA, Pershouse MA, Jasser SA, Yung WAK, Lin H, Ligon AH, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-362.
14. Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk A, Frierson HF, Theodorescu D: PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its phosphatase activity. Oncogene 2004;23:6788-6797.
15. Aveyard JS, Skilleter A, Habuchi T, Knowles MA: Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999;80:904-908.
16. Cairns P, Evron E, Okami K, Halachmi N, et al: Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder tumours. Oncogene 1998;16:3215-3218.